Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (vol 15, pg 163, 2020)

Ramanathan, RK; Von Hoff, DD; Eskens, F; Blumenschein, G; Richards, D; Genvresse, I; Reschke, S; Granvil, C; Skubala, A; Pena, C; Mross, K

Von Hoff, DD (corresponding author), TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ 85004 USA.

TARGETED ONCOLOGY, 2020; 15 (6): 803

Abstract

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索